Published on

Published in: Education, Technology, Business
No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide


  1. 1. MICROSPHERESSubmitted to: Submitted by:Mr. Santosh Kumar Singh P. Swetha.Sugunan M.Pharm, Pharmceutics, 2nd sem.
  2. 2. CONTENT Introduction Advantages Polymer used for preparation General method of preparation Release of drug from microspheres Characterization of microspheres Applications
  3. 3. INTRODUCTION Microspheres are characteristically free flowing powders consisting of proteins or synthetic polymers which are biodegradable in nature and ideally having a particle size less than 200 μm. Types of Microspheres Microcapsule Micromatrix Spherical particle with size varying from 50 nm to 2 mm.
  4. 4. ADVANTAGESPotential use of microspheres in the pharmaceutical industry• Taste and odor masking• Conversion of oils and other liquids to solids for ease of handling• Protection of drugs against the environment (moisture, light etc.)• Separation of incompatible materials (other drugs or excipients)• Improvement of flow of powders• Aid in dispersion of water-insoluble substances in aqueous media,• Production of SR, CR, and targeted medications.
  5. 5. PHARMACEUTICALAPPLICATIONS Microencapsulated products currently on the market, such as aspirin, theophylline & its derivatives, vitamins, pancrelipase, antihypertensive, potassium chloride, progesterone, and contraceptive hormone combinations. Microencapsulated KCl is used to prevent gastrointestinal complications associated with potassium chloride. Microspheres have also found potential applications as injection, or inhalation products. Most encapsulation processes are expensive and require significant capital investment for equipment. An additional expense is due to the fact that most microencapsulation processes are patent protected.
  6. 6. . OTHER APPLICATIONS  Microcapsules are also extensively used as diagnostics, for example, temperature-sensitive microcapsules for thermographic detection of tumors.  In the biotechnology industry microencapsulated microbial cells are being used for the production of recombinant proteins and peptides.  Encapsulation of microbial cells can also increase the cell-loading capacity and the rate of production in bioreactors.  A feline breast tumor line, which was difficult to grow in conventional culture, has been successfully grown in microcapsules.  Microencapsulated activated charcoal has been used for hemoperfusion.  Paramedical uses of microcapsules include bandages with microencapsulated anti-infective substances.
  7. 7. POLYMERS USED IN THE MICROSPHERE PREPARATION Synthetic Polymers Natural Materials Proteins Non-biodegradable Albumins PMMA Gelatin Acrolein Collagen Epoxy polymers Carbohydrates Starch agarose Biodegradable Carrageenan Lactides and Glycolides Chitosan copolymers Chemically modified carbohydrates Polyalkyl cyanoacrylates Poly (acryl) dextran Polyanhydrides Poly(acryl)starch DEAE cellulose
  8. 8. Prerequisites for Ideal Microparticulate Carriers• Longer duration of action• Control of content release• Increase of therapeutic efficacy• Protection of drug• Reduction of toxicity• Biocompatibility• Sterilizability• Relative stability• Water solubility or dispersibility• Bioresorbability• Targetability• Polyvalent
  9. 9. MICROSPHERE MANUFACTURE Most important physicochemical characteristics that may be controlled in microsphere manufacture are: • Particle size and distribution • Polymer molecular weight • Ratio of drug to polymer • Total mass of drug and polymer
  10. 10. GENERAL METHODS OFPREPARATION• Single Emulsion techniques• Double emulsion techniques• Polymerization techniques - Normal polymerization - Interfacial polymerization• Coacervation phase separation techniques• Spray drying and spray congealing• Solvent extraction
  11. 11. SIMPLE EMULSION BASED METHOD Aq.Solution/suspension of polymer Stirring, Sonication Dispersion in organic phase (Oil/Chloroform) Chemical cross linking (Glutaraldehyde/FormaldeHeat denaturation CROSS LINKING hyde/ Butanol)Microspheres in organic phase Microspheres in organic phase Centrifugation, Washing, Separation MICROSPHERES
  12. 12. DOUBLE EMULSION BASED METHOD Aq.Solution of protein/polymer Dispersion in oil/organic phase Homogenization First emulsion (W/O) Addition of aq. Solution of PVA Multiple emulsion Addition to large aq. Phase Denaturation/hardening Microspheres in solution Separation, Washing, Drying MICROSPHERES
  13. 13. INTERFACIAL DEPOSITION TECHNIQUE First, the polymer is dissolved in acetone, then a phospholipid mixture (e.g., Epikuron") and benzyl benzoate are added to this solution. The resulting organic solution is poured into an aqueous phase containing a surfactant (e.g., poloxamer 188) under moderate stirring. Acetone diffuses immediately into the aqueous phase, inducing the deposition and the precipitation of the polymer around the oily droplets. Once the microcapsules are formed, acetone is eliminated under reduced pressure. Drugs intended to be encapsulated by this method must have a high solubility in the organic-oily phase, otherwise they diffuse from the oily solution and precipitate in the aqueous medium during particle formation.
  14. 14. A)NORMAL POLYMERIZATION Normal Polymerization is done by bulk, suspension, pption,emulsion and polymerization process.1. Bulk polymerization: Monomer Bioactive material Initiator Heated to initiate polymerization Initiator accelerate rate of reaction Polymer(Block) Moulded/fragmented Microspheres
  15. 15. B)SUSPENSION POLYMERIZATION Monomer Bioactive material Initiator Dispersion in water & stabilizer Droplet Vigorous ,Aggitation Polymerization by Heat Hardened microspheres Separation & Drying MICROSPHERES
  16. 16. C)EMULSION POLYMERISATIONMonomer/ Aq.Solution of NaOH,Bioactive material Initiator, Surfactant , Stabilizer Dispersion with vigorous stirring Micellar sol. Of Polymer in aqueous medium Polymerization Microspheres formation MICROSPHERES
  17. 17. INTERFACIAL POLYMERIZATION TECHNIQUE When two reactive monomers are dissolved in immiscible solvents, the monomers diffuse to the oil- water interface where they react to form a polymeric membrane. Drug is incorporated either by being dissolved in the polymerization medium or by adsorption onto the nanoparticles after polymerization completed. The nanoparticle suspension is then purified to remove various stabilizers and surfactants employed for polymerization by ultracentrifugation and re- suspending the particles in an isotonic surfactant-free medium. This technique has been reported for making polybutylcyanoacrylate or poly (alkylcyanoacrylate) nanoparticles.
  18. 18. PHASE SEPARATION METHOD Aqueous/Organic Solution of polymer Drug Drug dispersed or dissolved in polymer solution Phase seperation induced by various means Polymer rich globules Hardening Microspheres in aq./organic phase Separation, Washing, Drying MICROSPHERES
  19. 19. E) SPRAY DRYING Polymer dissolve in volatile organic solvent(acetone, dichloromethane) Drug dispersed in polymer solution under high speed homogenization Atomized in a stream of hot air Due to solvent evaporation small droplet or fine mist form Leads to formation of Microspheres Microspheres separated from hot air by cycloneseparator, Trace of solvent are removed by vacuum drying
  20. 20. F) SOLVENT EXTRACTION Drug is dispersed in organic solvent(water miscible organic solvent such as Isopropanol) Polymer in organic solvent Organic phase is removed by extraction with water .(This process decreasing hardening time for microspheres) Hardened microspheres
  21. 21. PREPARATION OF MICROSPHERES BY DESOLVATION OF ALBUMIN Gelatin and albumin nanospheres can be produced by the slow addition of a desolvating agent (neutral salt or alcohol) to the protein solution. Upon this addition, a progressive modification of the protein tertiary Structure is induced leading (when a certain degree of desolvation is obtained), to the formation of protein aggregates. Nanospheres are obtained by subsequent crosslinking of these aggregates with glutaraldehyde. To obtain small and monodispersed particles, it is important to maintain the system at a point just before coacervation is initiated. The addition of the desolvating agent is monitored by turbidimetry measurements of the system and must be stopped as soon as the turbidity increases, otherwise aggregates that are too large will be formed.
  22. 22. SALTING-OUT PROCESS An aqueous phase saturated with electrolytes (e.g., magnesium acetate, magnesium chloride) and containing PVA as a stabilizing and viscosity increasing agent is added under vigorous stirring to an acetone solution of polymer. In this system, the miscibility of both phases is prevented by the saturation of the aqueous phase with electrolytes, according to a salting-out phenomenon. The addition of the aqueous phase is continued until a phase inversion occurs and an o/w emulsion is formed.Then, a sufficient amount of pure water is added to disrupt theequilibrium between the two phases and to allow complete diffusion ofacetone into water, leading to polymer precipitation in the form ofspherical nanospheres
  23. 23. PREPARATION OF MICROSPHERES BY THERMAL DENATURATION OF ALBUMIN Once a high degree of dispersion is achieved, the emulsion is added dropwise. Immediate vaporization of the water contained in the droplets and to the irreversible denaturation of the albumin which coagulates in the form of solid nanospheres. The suspension is then allowed to cool down at room temperature or in an ice bath. Subsequently, the particles are submitted to several washings using large amounts of organic solvent (e.g., ether, ethanol, acetone) for complete removal of the oil.
  24. 24. Release pattern of drug frommicrospheres Naltroxone (vivitrol TM) microspheres (PLA-PLGA) the first approved alcohol dependence medication in USA: MECHANISM: The release pattern of naltroxone as a result of: absorbing water and swelling immediately after injection where the near surface drug is released first -as water absorption continues hydrolysis starts and after several days physical erosion begins. -further drug diffuse to the surrounding resulting in sustained release of medication with the elimination of water and carbon dioxide as degradation product of polymer matrix.
  26. 26. CHARACTERIZATION OF MICROSPHERES YIELD VALUES AND LOADING EFFICIENCY:Yield value = 100 x Obtained wgt. Of microspheres Theoretical wgt to be preparedLoading = 100 x actual amt. of drug obtained by extractioneffeciency theoretical wgt. of drug added in preparation MICROSPHERE MORPHOLOGY:In this the prepared loaded microsphere is analyzed by scanning electronic microscope(SEM)after palladium/gold coating of the samples on an aluminium strip.
  27. 27.  MICROSPHERE SIZE DISTRIBUTION: Mean size is determined by methods like Laser diffractometry method. BULK DENSITY MEASUREMENT: By dipping method. MEASUREMENT OF GLASS TRANSITION TEMP (Tg) BY DSC: Tg is measured by DSC for the blank (unloaded) and the prepared loaded microspheres. SURFACE CHEMISTRY BY ELECTRON SPECTROSCOPY: Done for chemical analysis. Provides means of determination of atomic composition of the surface.
  28. 28.  RELEASE STUDY: Carried out in phosphate saline buffer Ph 7.4. Two methods- 1. Rotating paddle dissolution appratus. 2. Dialysis method. ISOELECTRIC POINT: Microelectrophoresis apparatus is used to measure electrophoretic mobility of microspheres from which isoelectric point can be determined. DEGREE OF HYDRATION: Measured to evaluate water uptake by the system as a first step in biodegradation.
  29. 29. RECENT ADVANCEMENTSWINE FLU INFLUENZA DNA VACCINEENCAPSULATED IN PLGA MICROSPHEREDNA vaccine against Swine flu influenza encapsulated in poly(D,L)lactic co glycolic acid(PLGA) microspheres.Prepared by Emulsion evaporation method usingPLGA as biodegradable matrix formic polymer.PLGA microspheres containing DNA vaccine can be used to achieved prolonged released of plasmid DNA.
  30. 30.  s-PLLA/IBUPROFIN MICROSPHERES(2010)These are star shaped poly(L- lactide)loaded ibuprofen (s-PLLA/IBU) microspheres.Prepared using Solvent evaporation methodIBU could combine with s-PLLA well and part of PLLA were degraded after releasing.The drug encapsulating efficiency of s-PLLA/IBUmicrospheres is high and release of ibuprofen frommicrospheres is slow and effective.
  31. 31. APPLICATIONS Vaccine delivery – Improved antigenecity, Ag release,  Stabilization of Ag  Drug targeting ◦ Ocular: gelation with increased residence time ◦ Intranasal: protein and peptide delivery ◦ Oral  Magnetic microspheres  Immunomicrospheres  Chemoembolization  Imaging  Microsponges  Surface modified microspheres
  32. 32. REFERENCES www.google.com www.wikipedia.com www.autorsteam.com www.informahealthcare.com www.en.cnki.com.cn www.pharmainfo.net